capecitabine has been researched along with Soft Tissue Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berry, H; Dodwell, DJ; Gillibrand, A; Kumar, S; Perren, TJ; Velikova, G; Waters, SH | 1 |
| Barton, C; Button, P; de Fátima Dias Gaui, M; Hersberger, V; Jassem, J; Morales-Vasquez, F; Pivot, X; Reyes, DO; Torres, AA; Wardley, AM; Zetina, LM | 1 |
| Banerji, U; Johnston, SR; Kendall, A; O'Brien, M; Smith, IE; Walsh, G; Yap, YS | 1 |
| Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Ceccolini, M; Fedeli, A; Fedeli, SL; Giordani, P; Rossi, D | 1 |
| Dugan, U; Edwards, C; Feigin, K; Hudis, C; Norton, L; Patil, S; Tan, KL; Theodoulou, M; Traina, TA | 1 |
4 trial(s) available for capecitabine and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; International Agencies; Liver Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Soft Tissue Neoplasms; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2010 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prodrugs; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate | 2008 |
Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Soft Tissue Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Models, Biological; Prodrugs; Soft Tissue Neoplasms; Thoracic Neoplasms | 2008 |
2 other study(ies) available for capecitabine and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2009 |
Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Retrospective Studies; Soft Tissue Neoplasms; Treatment Outcome; Viscera | 2007 |